An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus

Por Lin, De-Xin, Zhang, Qi-Yu, Li, Xuan, Ye, Qi-Wen, Lin, Fen, Li, Lin-Li
Publicado em 2010

Implementation of a Fast-Track Clinical Pathway Decreases Postoperative Length of Stay and Hospital Charges for Liver Resection

Por Lin, De-Xin, Li, Xuan, Ye, Qi-Wen, Lin, Fen, Li, Lin-Li, Zhang, Qi-Yu
Publicado em 2011

Steered Molecular Dynamics Simulations Reveal the Likelier Dissociation Pathway of Imatinib from Its Targeting Kinases c-Kit and Abl

Por Yang, Li-Jun, Zou, Jun, Xie, Huan-Zhang, Li, Lin-Li, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado em 2009

Clinical and genetic study of a juvenile⁃onset Huntington disease

Por Ying HAO, Yuan⁃yuan CHEN, Wei⁃hong GU, Guo⁃xiang WANG, Hui⁃zi MA, Li⁃lin LI, Kang WANG, Miao JIN, Xiao⁃hui DUAN
Publicado em 2012-06-01

Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers

Por Zhou, Jian-Ping, Chen, Xin, Feng, Shan, Luo, Shi-Dong, Pan, You-Li, Zhong, Lei, Ji, Pan, Wang, Ze-Rong, Ma, Shuang, Li, Lin-Li, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado em 2011

SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

Por Ma, Shuang, Yang, Ling-Ling, Niu, Ting, Cheng, Chuan, Zhong, Lei, Zheng, Ming-Wu, Xiong, Yu, Li, Lin-Li, Xiang, Rong, Chen, Li-Juan, Zhou, Qiao, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado no Sci Rep (2015)

A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

Por Zhang, Nannan, Zhang, Guo, Liu, Ning, Lin, Wanting, Ji, Sen, Zheng, Mingwu, Chen, Kai, Liang, Xiao, Li, Guobo, Ma, Yu, Zhu, Jun, Niu, Ting, Li, Lin-Li, Li, Jiong, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado no Oncotarget (2017)